ClinicalTrials.gg

Program

taletrectinib

Also written as “Taletrectinib”, “AB-106” and “DS6051b”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Neoplasms, led by 2 companies.

Furthest: phase 3, since Aug 12, 202411 company-led studies, 5 open or runningNext primary completion: Feb 2, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Nuvation Bio105 open or runningphase 3since Aug 12, 2024Oct 15, 2014Feb 2, 2027phase 1 · NCT07742384
Daiichi Sankyo10 open or runningphase 1since Feb 2, 2016Feb 2, 2016none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 15, 2014First study: phase 1 study in NeoplasmsNew to Nuvation BioNuvation Bio · NCT02279433 · 46 enrolled · United States
  2. Feb 2, 2016Daiichi Sankyo's first study: phase 1 study in Advanced Solid Malignant TumorsNew to Daiichi SankyoDaiichi Sankyo · NCT02675491 · 15 enrolled · Japan
  3. May 12, 2020Phase 2 study in Carcinoma, Non-Small-Cell LungNuvation Bio · NCT04395677 · 173 enrolled · China
  4. Oct 30, 2020Phase 2 study in Solid TumorNuvation Bio · NCT04617054 · 14 enrolled · China
  5. May 27, 2021Phase 2 study in Carcinoma, Non-Small-Cell LungNuvation Bio · NCT04919811 · 217 enrolled · United States, Canada, China and more
  6. Jul 9, 20212 phase 1 studies in Solid TumorNuvation Bio · NCT05357911, NCT05357820
  7. Oct 26, 2022Phase 1 study in Pharmacokinetic StudyNuvation Bio · NCT05609929 · 24 enrolled · China
  8. Aug 12, 2024Phase 3 study in Carcinoma, Non-Small-Cell LungNuvation Bio · NCT06564324 · 194 planned · China
  9. Aug 18, 2025Phase 3 study in Carcinoma, Non-Small-Cell LungNuvation Bio · NCT07154706 · 180 planned · United States, Canada, China
  10. Jul 13, 2026Phase 1 study in Healthy Adult ParticipantsNuvation Bio · NCT07742384 · 56 planned

Ahead

  1. Feb 2, 2027Primary completion: phase 1 study in Healthy Adult ParticipantsNuvation Bio · NCT07742384
  2. Jan 2029Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungNuvation Bio · NCT06564324
  3. Aug 30, 2030Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungNuvation Bio · NCT07154706

TargetBeta

“An orally available inhibitor of the receptor tyrosine kinases C-ros oncogene 1 (ROS1) and the neurotrophic tyrosine receptor kinase (NTRK) types 1, 2 and 3, ”NCIt, by rule
“Proto-oncogene tyrosine-protein kinase ROS inhibitor; Neurotrophic tyrosine kinase receptor inhibitor”ChEMBL 37, by rule

Other programs on the same 4 targets

ProgramCompanyFurthest phaseStudies
repotrectinibruleBristol-Myers Squibbphase 39

Studies

All 11 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07742384Healthy Adult Participants1Not yet recruitingNuvation BioFeb 2, 202756
NCT07154706Carcinoma, Non-Small-Cell Lung · United States, Canada, China3RecruitingNuvation BioAug 30, 2030180
NCT06564324Carcinoma, Non-Small-Cell Lung · China3RecruitingNuvation BioJan 2029194
NCT05609929Pharmacokinetic Study · China1CompletedNuvation BioJan 20, 202324
NCT05357911Solid Tumor · China1CompletedNuvation BioAug 20, 202116
NCT05357820Solid Tumor · China1CompletedNuvation BioDec 3, 202156
NCT04919811Carcinoma, Non-Small-Cell Lung · United States, Canada, China and more2Active, not recruitingNuvation BioJun 11, 2025217
NCT04617054Solid Tumor · China2TerminatedNuvation BioDec 6, 202414
NCT04395677Carcinoma, Non-Small-Cell Lung · China2Active, not recruitingNuvation BioJun 7, 2024173
NCT02675491Advanced Solid Malignant Tumors · Japan1CompletedDaiichi SankyoDec 27, 202115
NCT02279433Neoplasms · United States1CompletedNuvation BioMar 201946

How it is read

Names in the registry

  • “Taletrectinib”, 5 entries
  • “AB-106”, 2 entries
  • “DS6051b”, 1 entry
  • “DS-6051b”, 1 entry
  • “AB-106, Itraconazole”, 1 entry

Codes read as this program: AB106.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.